8-K: Bone Biologics Corporation Announces At-The-Market Offering of Common Stock

Bone Biologics Corporation has entered into an agreement with H.C. Wainwright & Co., LLC to sell up to $1,143,121 of its common stock through an at-the-market offering program.

Summary

• Bone Biologics Corporation has entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC.
• The company plans to sell shares of its common stock from time to time through an at-the-market offering program.
• The aggregate market value of shares eligible for sale is currently $1,143,121.
• H.C. Wainwright will receive a commission of 3.0% of the gross proceeds from each sale of shares.
• The company will also reimburse H.C. Wainwright for certain expenses up to $100,000, plus additional fees for due diligence sessions.
• The offering will terminate when the shares with an aggregate sales price of $1,143,121 are sold or the agreement is terminated.
• The shares will be issued pursuant to a prospectus supplement dated September 27, 2024, and an accompanying base prospectus dated July 11, 2022.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is raising capital, which can be seen as a positive for growth, it also introduces potential dilution for existing shareholders. The terms of the offering are standard, and there are no indications of significant issues.

Positives

• The at-the-market offering provides Bone Biologics with a flexible way to raise capital.
• The agreement allows the company to sell shares over time, potentially minimizing market impact.
• The company has secured a sales agent to manage the offering.

Negatives

• The company will incur commission expenses of 3.0% on the gross proceeds from each sale.
• The company will incur additional expenses up to $100,000, plus additional due diligence fees.
• The offering could potentially dilute existing shareholders' ownership.

Risks

• The company is not obligated to sell any shares under the agreement and may suspend the offering at any time.
• The market price of the company's stock could be negatively impacted by the offering.
• There is no guarantee that the company will be able to sell all of the shares offered.

Future Outlook

The company intends to use the proceeds from the offering for general corporate purposes, but specific details are not provided in this document.

Management Comments

• The company has entered into an agreement with H.C. Wainwright & Co., LLC to sell shares of its common stock.

Industry Context

At-the-market offerings are a common method for publicly traded companies to raise capital, providing flexibility and potentially minimizing market impact compared to traditional underwritten offerings. This is a standard practice in the biotech industry.

Comparison to Industry Standards

• At-the-market offerings are a common financing tool for small-cap biotech companies like Bone Biologics.
• The 3% commission rate is within the typical range for such offerings.
• The maximum offering size of $1,143,121 is relatively small, suggesting a need for modest capital infusion.
• Comparable companies that have used ATM offerings include Xtant Medical Holdings, Inc. (XTNT) and Apyx Medical Corporation (APYX), which have similar market caps and capital needs.

Stakeholder Impact

• Shareholders may experience dilution of their ownership due to the issuance of new shares.
• The company will have additional capital to fund its operations.
• The company's financial position may be strengthened by the capital raise.

Next Steps

• The company will sell shares of its common stock through H.C. Wainwright & Co., LLC.
• The company will file a prospectus supplement with the SEC.
• The company will monitor the market and sell shares as needed.

Key Dates

Keywords

at-the-market offering, common stock, capital raise, H.C. Wainwright, securities, offering agreement, BBLG, equity financing